The market size of wearable injectors will be approximately USD 21.98 bn in 2030 at 15.2 % CAGR for the forecast period 2022-2030. The wearable injectors market is affected by many factors that together shape its dynamics and growth. One of the main push factors is the growing burden of chronic diseases and the escalating need for convenient and patient-friendly dosage formats. As a result of an increasing number of chronic diseases like diabetes, cardiovascular disorders and autoimmune diseases, there appears a necessity for precise and easy drug delivery methods. Injectable wearables, which are used in self-administration of medications, provide patients with a much friendlier and not so invasive way, contributing to the market's growth.
Technological advancements are the key factors in the development of the wearable injectors market. Continuous revolution in wearable device technology comprising of materials as well as connectivity features and sensor capabilities improves efficacy and usability of wearable injectors. Rapid features, like dose tracking, reminders, and mobile applications connectivity, are key to better adherence and patient engagement that promote the implementation of wearable injectors.
Regulatory considerations take the fore in the wearable injectors market. Strict standardized regulations and approvals are key in achieving the safety and effectiveness of these devices. Compliance with regulatory standards affects product development, manufacturing practice and market entry strategy for wearable injector manufacturers. Awareness to regulatory directives boosts trust among healthcare professionals and patients which aids in the widespread use of wearable injectors as dependable and controlled drug delivery devices.
Additionally, the dynamics of the market are also affected by economic factors such as healthcare expenditure and reimbursement policies. The economic potential of introducing wearable injectors is affected by the reimbursement policies and coverage. Economic concerns are a driving force behind the affordability of these devices for patients, and whether doctors in regions where cost-effectiveness matters in the decision-making process take them on or not.
Territorial disparity is what creates the market environment, and each region is susceptible to specific health care problems and patient specifications. The magnitude of the certain chronic diseases, the healthcare infrastructure, and patient demographics in the geographical area can affect how much demand there is for wearable injectors. One of the ways manufacturers tailor their strategies is by responding to the specific market requirements and regulation of different markets.
Report Attribute/Metric | Details |
---|
The wearable injectors market has been segmented into type, usage, mechanism of action, therapeutic area, and end-user.
The wearable injectors market, on the basis of type, has been segmented into on-body wearable injectors, off-body wearable injectors, and hand-held wearable injectors.
The wearable injectors market, by usage, has been segmented into disposable and semi-reusable.
The market, by mechanism of action, has been segmented into spring based, motor driven, rotary pump, expanding battery, pressurized gas, and collapsible reservoir.
The market, by therapeutic area, has been segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes, and others.
The market, by end-user, has been segmented into hospitals, clinics, homecare, ambulatory surgery centers, others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The wearable injectors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European wearable injectors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The wearable injectors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The wearable injectors market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
West Pharmaceutical Services, Inc., Valeritas, Inc., Eli Lilly and Company, YPSOMED, Amgen Inc., Becton, Dickinson and Company (BD), CeQur SA, SteadyMed Therapeutics, Inc., BioSpace, Enable Injections, and Sensile Medical AG are some of the key players in the wearable injectors market.
Regional Market Summary
Wearable Injectors Market Share (%), by Region
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the wearable injectors market owing to a well-developed healthcare sector, rising prevalence of autoimmune and chronic disease and growing healthcare expenditure. According to a report published by American Autoimmune Related Diseases Association (AARDA) in April 2017, in the US approximately 50 million people i.e. nearly 20% population suffer from autoimmune diseases. Additionally, government funding in this region contributes to the growth of the market.
Europe is expected to hold the second largest position in the wearable injectors market. The market growth in this region is attributed to the growing prevalence of chronic diseases, the availability of funds for research, and increasing healthcare expenditure. According to a report published by the NSD Alliance in July 2017, 1/3rd of the European population above the age of 15 years suffer from a chronic disease.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of chronic diseases like diabetes, cardiovascular diseases and increasing government funding for the healthcare sector. According to a study published in the Asian Pacific Journal of Tropical Biomedicine journal in 2014, it was estimated that about 150 million diabetic patients reside within the region, out of which more than 95% have type 2 diabetes mellitus.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.Recent Development
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)